Stockholm’s BioLamina has secured a €20 million loan from the European Investment Bank to accelerate development of cell therapies targeting serious chronic diseases. The financing is structured as venture debt, a long-term funding model designed for high-growth biotech firms. This loan will allow BioLamina to scale production of its cell culture matrices, which are critical for advancing therapies in areas such as diabetes, cardiovascular disorders and neurodegenerative conditions.
The EIB loan follows BioLamina’s recent expansion into new European markets. The company specializes in matrix biology, producing synthetic substrates that mimic natural cell environments. These substrates are essential for growing cells in labs, a process that underpins the development of cell-based treatments. The financing will also support hiring and facility upgrades in Stockholm.
BioLamina’s technology has gained recognition for its role in improving the efficiency of cell therapy production. The company collaborates with academic institutions and pharmaceutical partners across Europe. The EIB’s involvement signals growing institutional confidence in Sweden’s biotech sector, which has seen increased investment in recent years.
The loan agreement includes provisions for performance milestones tied to clinical progress. BioLamina must meet specific development targets within set timelines to access additional tranches of funding. This structure aligns the company’s growth with measurable scientific achievements.
Sweden’s biotech ecosystem benefits from strong research infrastructure and government incentives. BioLamina’s success reflects broader trends in Europe’s push to reduce reliance on imported medical technologies. The company’s work could influence future standards in cell therapy manufacturing.
Source: eu-startups.com